SARS-CoV-2 seroprevalence in pregnant women in Kilifi, Kenya from March 2020 to March 2022

Koech, A; Omuse, G; Mugo, AG; Mwaniki, IG; Mutunga, JM; Mukhanya, MW; Wanje, O; Mwashigadi, GM; Katana, GG; Craik, R; von Dadelszen, P; Le Doare, K; Temmerman, M; periCOVID-Africa,; Network, TP; Freyne, B; Kawaza, K; Lissauer, S; Sommerfelt, H; Etti, M; Musoke, P; Mboizi, R; Cose, S; Nankabirwa, V; Hookham, L; Voysey, M; Cantrell, L; Noble, A

Journal article

SARS-CoV-2 seroprevalence in pregnant women in Kilifi, Kenya from March 2020 to March 2022

Abstract:: Background: Seroprevalence studies are an alternative approach to estimating the extent of transmission of SARS-CoV-2 and the evolution of the pandemic in different geographical settings. We aimed to determine the SARS-CoV-2 seroprevalence from March 2020 to March 2022 in a rural and urban setting in Kilifi County, Kenya. Methods: We obtained representative random samples of stored serum from a pregnancy cohort study for the period March 2020 to March 2022 and tested for antibodies against the spike protein using a qualitative SARS-CoV-2 ELISA kit (Wantai, total antibodies). All positive samples were retested for anti-SARS-CoV-2 anti-nucleocapsid antibodies (Euroimmun, ELISA kits, NCP, qualitative, IgG) and anti-spike protein antibodies (Euroimmun, ELISA kits, QuantiVac; quantitative, IgG). Results: A total of 2,495 (of 4,703 available) samples were tested. There was an overall trend of increasing seropositivity from a low of 0% [95% CI 0–0.06] in March 2020 to a high of 89.4% [95% CI 83.36–93.82] in Feb 2022. Of the Wantai test-positive samples, 59.7% (95% CI 57.06–62.34) tested positive by the Euroimmun anti-SARS-CoV-2 NCP test and 75.9% (95% CI 73.55–78.17) tested positive by the Euroimmun anti-SARS-CoV-2 QuantiVac test. No differences were observed between the urban and rural hospital but villages adjacent to the major highway traversing the study area had a higher seroprevalence. Conclusion: Anti-SARS-CoV-2 seroprevalence rose rapidly, with most of the population exposed to SARS-CoV-2 within 23 months of the first cases. The high cumulative seroprevalence suggests greater population exposure to SARS-CoV-2 than that reported from surveillance data

Publication status:: Published

Peer review status:: Peer reviewed

Actions

Email

Email this record

Send the bibliographic details of this record to your email address.

Your Email
Please enter the email address that the record information will be sent to.

-
Your message (optional)
Please add any additional information to be included within the email.
Share
Cite

Cite this record

APA Style

Koech, A., Omuse, G., Mugo, A. G., Mwaniki, I. G., Mutunga, J. M., Mukhanya, M. W., Wanje, O., Mwashigadi, G. M., Katana, G. G., Craik, R., von Dadelszen, P., Le Doare, K., Temmerman, M., periCOVID-Africa, Network, T. P., Freyne, B., Kawaza, K., Lissauer, S., Sommerfelt, H., … Noble, A. (2023). SARS-CoV-2 seroprevalence in pregnant women in Kilifi, Kenya from March 2020 to March 2022. Frontiers in Public Health, 11, 1292932–1292932.

MLA Style

Koech, A, et al. “SARS-CoV-2 Seroprevalence in Pregnant Women in Kilifi, Kenya from March 2020 to March 2022.” Frontiers in Public Health, vol. 11, 2023, pp. 1292932–32.

Chicago Style

Koech, A, G Omuse, AG Mugo, et al. 2023. “SARS-CoV-2 Seroprevalence in Pregnant Women in Kilifi, Kenya from March 2020 to March 2022.” Frontiers in Public Health 11: 1292932–32.
Print